{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019641","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.814073+00:00","generated_at":"2026-06-15T09:46:17.299865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1","bullets":["Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.","R&D expenses $15.9M (up from $10.2M); G&A $6.5M (up from $4.9M).","First patient enrolled in EGFR-TRACTr (JANX008) Phase 1 for solid tumors.","Interim clinical update for PSMA-TRACTr (JANX007) expected in 2H 2023.","PD-L1xCD28 TRACIr (JANX009) IND on track for submission in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019641","json":"https://secwatch.observer/filing/0000950170-23-019641.json","markdown":"https://secwatch.observer/filing/0000950170-23-019641.md","text":"https://secwatch.observer/filing/0000950170-23-019641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/0000950170-23-019641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/janx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:46:17.299865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4a37b34099e27c321930e9f14e25afcb9ea2cd0","claim":"Janux Therapeutics, Inc. reported the three months ended March 31, 2023 results: net income net loss of $17.5 million.","evidence_excerpt":"On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/0000950170-23-019641-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"net loss of $17.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}